SPECIAL ISSUE I YEARBOOK 2020

PHARMA ON

THE FRONTLINE

Up against a complex and evolving adversary, pharma led the fight to find a cure for Covid-19 in 2020

Repurposing drugs for Covid-19

What happens to whistleblowers?

Debunking puberty blocker myths

02/24/2024 11:00:00

12/18/2020 00:00:00

Go to article: Home | Pharma on the frontline Go to article: In this issue Go to article: Mimotopes Go to article: Contents Go to article: VEGA Australia Go to article: Biosynth Carbosynth Go to article: Ehlers-Danlos syndrome: The zebra in the room Go to article: Cytiva Company Insight Go to article: Cytiva Go to article: Turning pharma green: an eco-wish list for the industry Go to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: No time to waste: repurposing drugs to tackle covid-19 Go to article: Intellectual property in the time of Covid-19 Go to article: Recce Pharma: a new frontier in the fight against AMR Go to article: A century of cultures: celebrating the world’s oldest lab culture collection Go to article: Debunking myths about puberty blockers for transgender children Go to article: Crabby concoctions: why pharma’s thirst for crustacean blood is up for debate Go to article: From antitoxins to Covid-19 drugs: charting the history of antibody drugs Go to article: Events Go to article: Next issue